Motivation and Objectives
Next Generation Sequencing techniques are allowing the determination of new somatic mutations involved in cancer development. One of the Bioinformatics' challenges is to develop computational tools able to distinguish in a reliable way the germline polymorphisms present in healthy tissue from the somatically acquired mutations in tumor cells. There has been described two families of somatic variant calling approaches, in earlier one somatic variants have been detected by independently genotyping both samples and subtracting the results (i.e Samtools, Unified Genotyper), in contrast to new one which make simultaneous analysis of tumor and normal datasets from the same individual (i.e. Strelka, JointSNVMix). In our knowledge, just a few reliable studies compare their results. The aim of this work is to compare these two different somatic variant calling approaches analyzing sequenced exome of tumor-matched normal sample pairs.
Methods
A new workflow that allows comparison of different variant calling methods (Samtools v. 0,1,16 (Li et al., 2009 ), Unified Genotyper v. 1,6 (DePristo et al., 2011 ), Strelka v. 0,4,6 (Saunders et al., 2012 and JointSNVMix v. 0,8 (Roth et al., 2012) ) has been developed. This workflow has been tested using two exome paired-end matched tumornormal data sets obtained from pediatric cancers: dataset A (Illumina GAIIx, two patients -two tumors) and dataset B (Illumina HiSeq, 11 patients -13 tumors). The threshold used for Samtools was selected by default, for Unified Genotyper was the recommended configuration in the GATK best practice guidelines, for Strelka was the recommended configuration with a quality score ≥15, and for JointSNVMix was P(somatic) ≥ 0,8. Somatic variants reported by all methods were manually curated using IGV (Integrative Genomics Viewer; Robinson et al., 2011) .
Results and Discussion
The results obtained analyzing Dataset A are showed in Table 1 . The simultaneous analysis of tumor-normal paired sequence used by Strelka or JointSNVMix, gives a lower false positive variant number than independent analysis of the tumor and normal data, approach followed by software like Samtools and Unified Genotyper, both commonly used in variant calling workflows.
Preliminary results prove that the determination of somatic mutations in tumors requires that the specific algorithms are able to analyze, in a combined way, the information provided by tumor DNA and constitutional DNA, and thus enabling better precise distinction between germinal and somatic variants. 
